Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:05:43.177Z.
Calculation as of: 2026-10-06T17:05:43.177Z.
Quote observation: 2026-10-06T16:58:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c4088ee3877f0fa8fb1d478ebd945bbdf3f6f56484e99899685bc9bfb173ee48
PEG RATIO
N/A
Aptevo Therapeutics Inc.
Market Cap
$3.98M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | $3.98M | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $4.01M | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.07M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.84M | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.79M | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.23M | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.57M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.53M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
